1. Home
  2. DKI vs AIMD Comparison

DKI vs AIMD Comparison

Compare DKI & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DKI

DarkIris Inc. Class A Ordinary Shares

HOLD

Current Price

$3.91

Market Cap

10.0M

Sector

N/A

ML Signal

HOLD

Logo Ainos Inc.

AIMD

Ainos Inc.

HOLD

Current Price

$1.48

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DKI
AIMD
Founded
2018
1984
Country
Hong Kong
United States
Employees
19
41
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0M
11.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DKI
AIMD
Price
$3.91
$1.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
10.6K
37.2K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$1.26
52 Week High
$11.80
$4.50

Technical Indicators

Market Signals
Indicator
DKI
AIMD
Relative Strength Index (RSI) 38.31 42.41
Support Level $3.96 $1.35
Resistance Level $5.14 $1.75
Average True Range (ATR) 0.19 0.14
MACD -0.07 -0.02
Stochastic Oscillator 13.68 27.69

Price Performance

Historical Comparison
DKI
AIMD

About DKI DarkIris Inc. Class A Ordinary Shares

Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.

About AIMD Ainos Inc.

Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.

Share on Social Networks: